Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

JA08-Negotiating-Payer-Contracts
State Oncology Society Leaders Gather in Chicago Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 State Oncology Society Leaders Gather in Chicago To cite this article: (1999) State …
A Chance for a Change Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 A Chance for a Change Lee E. Mortenson To cite this article: Lee E. Mortenson (2000) A Chance for a Change, …
An Interview with ACCC's New President An Interview with ACCC's New President: Teresa D. Smith, R.N., M.S.N. Q: Welcome to y OI4T n~ /X?sitiOll . s Acee President: Pu ase tell Jd Aboul YOUTb4tckgrollnd find experience. 1 Thank rou,Currenrly, I am director 0 oncology at th e University of Wisconsin H ospitals and C linics in Madison, Wise. Pri or to my arrival in Wisconsin. I was th e …
Accelerated Approvals Reconsidered Tabrecta® (capmatinib hydrochloride) – Novartis was notified that the accelerated approval it had received for use of its kinase inhibitor for treating adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping (as detected by an FDA-approved test) has …
Oncodermatology is a rapidly developing field that is attracting significant interest and generating new literature in the context of cancer treatment strategies.
Accelerated Approvals Reconsidered Tabrecta® (capmatinib hydrochloride) – Novartis was notified that the accelerated approval it had received for use of its kinase inhibitor for treating adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping (as detected by an FDA-approved test) has …
Accelerated Approvals Reconsidered Tabrecta® (capmatinib hydrochloride) – Novartis was notified that the accelerated approval it had received for use of its kinase inhibitor for treating adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping (as detected by an FDA-approved test) has …
ASSOCIATION OF COMMUNITY CANCER CENTERS Examining the Financial Aspects of Cancer Biomarker Testing for Prior Authorizations TIP: Confused about these terms? Cancer care programs can follow the recommendations out- lined on commoncancertestingterms.org when discussing biomarker testing. TIP: Do not confuse genomic testing (tumor vari- ant) with genetic testing (inherited …
ASSOCIATION OF COMMUNITY CANCER CENTERS ONCOLOGY P H A R M AC Y EDUCATION N E T W O R K Healthcare providers use biosimilars to treat cancer and control treatment side effects. Biosimilars are approved by the U.S. Food and Drug Administration (FDA). This fact sheet answers common questions about biosimilars. What are biosimilars? Biosimilars are highly similar and equally effective …
FAN-Its-All-in-How-You-Phrase-It-Answer-Key
AHFS Drug Information Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 AHFS Drug Information Gerald K. McEvoy To cite this article: Gerald K. McEvoy (1994) AHFS Drug Information, …
Continued on back About a Cancer Diagnosis Cancer takes many forms. No two people have the same cancer journey. This sheet explains some of the ways that doctors talk about cancer. It may help you to understand your cancer. What is a cancer stage? When a person is first found to have cancer, doctors do exams and tests to learn the cancer’s stage. The stage describes …
SO04-A-Model-Patient-Navigation-Program
Molecular-Testing-Molecular-Tests-Not-Ordered-for-Eligible-Patients
Building on the success of BiomarkerLIVE’s launch, Phase 2 will help cancer providers better understand what is needed to facilitate the integration of precision medicine into everyday practice.
To help older patients become digitally literate, the Patient Empowerment Network offers a free program that teaches older adults with cancer valuable technology skills.
Listen to ACCC's Matt Devino and President of the Empire State Hematology & Oncology Society, Rahul Seth, DO, discuss why every voice is critical in grassroots advocacy efforts on both the federal and state level, and how cancer professionals who moonlight as patient advocates can help improve access to care and reduce financial toxicity for people living with cancer.
1 Copyright© 2024 ADVI Health. All Rights Reserved. On May 30, 2024, CMMI released a request for applications (RFA) to solicit applications for a second cohort of participants in the Enhancing Oncology Model (EOM) and to highlight changes to the model. • The RFA is for a second cohort of EOM participants and payers. • The second cohort will begin participation in EOM on July 1, 2025, and end …
JF06-Tools